Rho GDP-Dissociation Inhibitor 2 Inhibits C-X-C Chemokine Receptor Type 4-Mediated Acute Lymphoblastic Leukemia Cell Migration

Jixian Luo*, Junting Wang, Huiguang Zheng and Lan Wang

School of Life Sciences, Shanxi University, Taiyuan, China

Although we currently have a good understanding of the role C-X-C chemokine receptor type 4 (CXCR4) plays in T cell acute lymphoblastic leukemia (T-ALL), the mechanism of CXCR4-mediated T-ALL migration remains elusive. Therefore, we focus on the downstream signals of CXCR4 that contribute to T-ALL cell migration in this study. Rho GDP-dissociation inhibitor 2 (RhoGDI2) is expressed preferentially in lymphocytes. It interacts with and regulates the activation of Rho proteins by inhibiting the dissociation of GDP and the binding of GTP. In a previous study, we demonstrated that RhoA and RhoC are activated and required for CXCR4-mediated JURKAT cell migration. In the present work, we investigate the role of RhoGDI2 in CXCR4-mediated T-ALL cell migration. Results show that RhoGDI2 sh2 significantly releases its inhibition effects on T-ALL cell migration toward CXCL12 (C-X-C motif chemokine ligand 12). Phosphorylation of RhoGDI2 on Y24 and Y153 releases RhoA and RhoC from RhoGDI2, which recovers CXCR4-mediated migration toward CXCL12 although the phosphorylation of Y130 has less effect on RhoA or RhoC binding. Furthermore, Src is activated by CXCL12. Transfection of siRNAs to Src reduces CXCR4-mediated migration. Src is required for the phosphorylation of RhoGDI2 on Y153, and ABL1 is activated by CXCL12 and responsible for the phosphorylation of RhoGDI2 on Y24 and Y130. Similarly, knockdown of the expression of ABL1 by siRNAs reduces the CXCR4-mediated migration. Therefore, RhoGDI2 may be a brake for CXCR4-positive T-ALL migration. Because migration is a prerequisite for infiltration of leukemia, this work may suggest the possible involvement of RhoGDI2 in infiltration of T-ALL.

Keywords: RhoGTPases, migration, leukemia, chemokines, receptor

INTRODUCTION

Acute lymphoblastic leukemia (ALL) accounts for 70–80% of all leukemia (1). Although the development of clinical treatments have resulted in a cure rate of about 85–90% (2), relapses occur in about 15–20% of children and are still the major reason for early age mortality (3). CXCR4-mediated infiltration of the central nervous system is a severe trait of T cell acute
lymphoblastic leukemia (T-ALL) and correlates with relapses (4). Accumulating data have demonstrated that high expression of CXCR4 is associated with infiltration into spleen, liver, lymph nodes, and CNS in T-ALL (4–8). In the critical process of infiltration, transendothelial migration of leukemic cells is required to exit the blood stream into target organs, which is the prerequisite for infiltration (9). Therefore, the mechanism of CXCR4-mediated migration of T-ALL cells is focused on in the following study.

Rho GDP-dissociation inhibitor 2, RhoGDI2, alternative name Ly-GDI or Rho-GDI beta, is expressed preferentially in lymphocytes (10). It interacts with the Rho proteins, including RhoA (11), Cdc42 or Rac1 (12), and Rac2 (13), and regulates the activation of Rho proteins by inhibiting the dissociation of GDP and the subsequent binding of GTP (10, 14). Therefore, it regulates reorganization of the actin cytoskeleton mediated by Rho family members (15). RhoGDI2 high expression has been found in ALL cell lines, for example, the JURKAT T-ALL cell line (16). However, the function of RhoGDI2 in ALL migration remains largely unknown. In this paper, we design experiments to investigate the role of RhoGDI2 in CXCR4-mediated T-ALL cell migration.

**MATERIALS AND METHODS**

**Cell Lines**
JURKAT (Clone E6-1) and CCRF-CEM cell lines were kindly provided by Stem Cell Bank, Chinese Academy of Sciences. HEK293T cells were purchased from the American Type Culture Collection (ATCC).

**Reagents or Antibodies**
AMD3100 (S8030, Plerixafor, antagonist against CXCR4) was purchased from Selleckchem. Poly-D-lysine (C0312) was purchased from Beyotime Biotechnology. ATP (disodium salt) (IA0590) was purchased from Solarbio.

Recombinant human Src protein (ab79635, His tag active Src) was purchased from Abcam. Recombinant human/feline/rhesus macaque (350-NS) was purchased from R&D systems.

Antibody to human CXCR4 (ab181020) and anti-GFP antibody (ab6556) were purchased from Abcam. Antibodies to RhoGDI2 (sc-271042) and ABL1 (sc-56887) were purchased from Santa Cruz biotechnology. Anti-RhoGDI2 (D262966) for Western blot assay, anti-ACTB (D110001), anti-Src antibody

**TABLE 1 | siRNA sequences or primers designed to construct the corresponding plasmids.**

| Name                          | Sequence                                                                 |
|-------------------------------|--------------------------------------------------------------------------|
| control (for RhoGDI2 sh2)     | 5′-GATCCCGTTCTCTCGAAGCGTGTCTAGTCAAGAAGGTGACAGGTGGAGAATTTTC3′              |
| RhoGDI2 sh2                    | 5′-GATCCCGTTCTCTCGAAGCGTGTCTAGTCAAGAAGGTGACAGGTGGAGAATTTTC3′              |
| control (for CXCR4 shRNAs)    | 5′-GATCCCGTTCTCTCGAAGCGTGTCTAGTCAAGAAGGTGACAGGTGGAGAATTTTC3′              |
| CXCR4 sh1                     | 5′-GATCCCGTTCTCTCGAAGCGTGTCTAGTCAAGAAGGTGACAGGTGGAGAATTTTC3′              |
| CXCR4 sh2                     | 5′-GATCCCGTTCTCTCGAAGCGTGTCTAGTCAAGAAGGTGACAGGTGGAGAATTTTC3′              |
| RhoGDI2 (Y24E)                | 5′-GATCCCGTTCTCTCGAAGCGTGTCTAGTCAAGAAGGTGACAGGTGGAGAATTTTC3′              |
| RhoGDI2 (Y130E)               | 5′-GATCCCGTTCTCTCGAAGCGTGTCTAGTCAAGAAGGTGACAGGTGGAGAATTTTC3′              |
| RhoGDI2 (Y153E)               | 5′-GATCCCGTTCTCTCGAAGCGTGTCTAGTCAAGAAGGTGACAGGTGGAGAATTTTC3′              |
| siRNA control                 | 5′-GATCCCGTTCTCTCGAAGCGTGTCTAGTCAAGAAGGTGACAGGTGGAGAATTTTC3′              |
| Src siRNA1                    | 5′-GATCCCGTTCTCTCGAAGCGTGTCTAGTCAAGAAGGTGACAGGTGGAGAATTTTC3′              |
| Src siRNA2                    | 5′-GATCCCGTTCTCTCGAAGCGTGTCTAGTCAAGAAGGTGACAGGTGGAGAATTTTC3′              |
| ABL1 siRNA1                   | 5′-GATCCCGTTCTCTCGAAGCGTGTCTAGTCAAGAAGGTGACAGGTGGAGAATTTTC3′              |
| ABL1 siRNA2                   | 5′-GATCCCGTTCTCTCGAAGCGTGTCTAGTCAAGAAGGTGACAGGTGGAGAATTTTC3′              |
| Lck siRNA1                    | 5′-GATCCCGTTCTCTCGAAGCGTGTCTAGTCAAGAAGGTGACAGGTGGAGAATTTTC3′              |
| Lck siRNA2                    | 5′-GATCCCGTTCTCTCGAAGCGTGTCTAGTCAAGAAGGTGACAGGTGGAGAATTTTC3′              |
(D221267), and anti-GST-Tag pAb (AE006) were purchased from Sangon Biotech Company. Rabbit mAb to phospho-Src family (Tyr416) (D49G4), rabbit mAb to RhoA (67B9), and rabbit mAb to RhoC (D40E4) were purchased from Cell Signaling Technology. Rabbit mAb to phospho-Lck family (Tyr394) (D155064) was purchased Sangon Biotech. Mouse anti-His-Tag mAb (AE003) was purchased from ABclonal. Monoclonal antibody to phosphotyrosine produced in mouse (PY20, P4110) was purchased from Sigma-Aldrich. Fast Mutagenesis System was purchased from TransGen Biotech.

rDNA Constructs
To construct GST-fused Crk-CTD domain plasmids, CRK-CTD was amplified by PCR using the cDNA from JURKAT cells as a template and cloned into the vector pGEX-4T-1. The open reading frame of the inserted DNA was confirmed by sequencing, and the expression of the GST-fused proteins was verified by SDS-PAGE. Plasmids expressing wild-type (WT) GST-tagged human RhoGDI2 and mutants (Y24F, Y130F, and Y153F) in pGEX-6p-1 vector, GFP-tagged WT human RhoGDI2 in lentiviral pWPXLd vector, and shRNAs targeting RhoGDI2 or random control in lentiviral pDSL_hpUGIP vector were kindly provided by Professor XL Zeng from Northeast Normal University, Changchun, China. Mutants expressing GST-tagged RhoGDI2 Y24E, Y130E, and Y153E and GFP-tagged RhoGDI2 Y24E, Y130E, and Y153E were amplified by PCR using point mutation kits of the Fast Mutagenesis System (K11209) from TransGen Biotech. In this PCR, WT RhoGDI2 plasmid was the template, and primers are shown in Table 1. Mutants expressing GST-tagged RhoGDI2 Y24E130E, RhoGDI2 Y24E153E, RhoGDI2 Y130E153E, and RhoGDI2 Y24E130E153E were amplified similarly by two or three rounds PCR using RhoGDI2 Y24E or Y130E as templates, and the mutants were verified with sequencing.

For CXC4 shRNA preparation, annealed double-stranded shRNA oligonucleotides shown in Table 1 were cloned into the XhoI and HpaI cloning sites of lentiviral pLL3.7 vector with GFP expressing sequence.

Generation of Lentiviruses and Transfection
RhoGDI2 WT, Y24E, Y130E, and Y153E in pWPXLd and CXC4 shRNAs in pLL3.7 or RhoGDI2 shRNA2 in pDSL_hpUGIP were transfected together with psPAX2 and pMD2 (at a ratio of 4:3:1) into HEK293T cells with lipofectamine 2000 (Invitrogen) to generate lentiviruses. Viral stocks were made to infect Jurkat cells or CCRF-CEM cells. After 72 h, cells were collected, and cell lysate was used in the following Western blot assay to detect interfering efficiency.

Small Interfering RNA
JURKAT or CCRF-CEM cells, 1.5 × 10^6, were seeded in each well of a 24-well plate precoated with 0.1 mg/ml poly-D-Lysine cultured in 500 μl RPMI 1640 medium without antibiotics in a 37°C incubator containing 5% CO2 for 20–24 h. Cells attached to poly-D-Lysine-coated wells were washed three times with PBS and then transiently transfected with small interfering RNAs (siRNAs) targeting Src, ABL1, or control siRNA using Lipofectamine 2000 following the manufacturer’s instructions for adherent cells. Four to 6 h after transfection, cells were replaced with complete medium. SiRNAs were used at 200 pM. After 48 h, cells were collected for the following Western blot assay to detect interfering efficiency or transwell assay.

Transwell Assay (in vitro Migration Assay)
The migration of JURKAT or CCRF-CEM cells was evaluated using a transwell chamber with 3-μm pores (Corning). Cells were starved in medium containing 0.5% FBS overnight. Then 3 × 10^5 cells were seeded in the upper wells, and 25 ng/ml CXCL12 was placed in the lower wells. The plates were incubated at 37°C for 4 h with 5% CO2. After each experiment, each upper well was gently taken away, and eight pictures of the cells that had migrated to the lower wells were taken randomly under a fourfold objective of a phase contrast microscope. Relative migration rate was the result of dividing the cell number of each group by that of the control group.

GST Pull-Down Assay
GST and GST-fused proteins (GST-CRK-CTD, GST-RhoGDI2-WT, GST-RhoGDI2-Y24E, GST-RhoGDI2 Y130E, GST-RhoGDI2 Y153E, GST-RhoGDI2 Y24E Y130E, GST-RhoGDI2 Y24E Y153E, GST-RhoGDI2 Y130E Y153E, GST-RhoGDI2 Y24E Y130E Y153E) were expressed in Escherichia coli strain BL21. The induction was performed by adding 1 mM isopropyl-β-d-thiogalactopyranoside (IPTG) to the culture with OD 1.0 at 37°C for 3 h. Whole bacteria lysates were applied to GST-BindTM Resin beads (D00172269, EMD Millipore Corp., MA, United States), and GST-tagged proteins were purified according to the manufacturer’s instructions. For pull-down experiments, JURKAT and CCRF-CEM cells were starved in medium containing 0.5% FBS. Then, 4 × 10^7 cells were lysed in pull-down lysis buffer (25 mM Tris, pH 7.5, 150 mM NaCl, 1% Non-ident P-40, 5% glycerol, 60 mM MgCl2) with freshly added PMSF, and 30 μl of each sample were taken for basal control. The left lysates were incubated with 25 μg GST-tagged proteins bound to glutathione Sepharose 4B beads at 4°C for 4 h. After three washes with lysis buffer, the bound proteins were analyzed by Western blot assay.

In vitro Kinase Assay
Escherichia coli BL21 expressing GST-RhoGDI2-WT, GST-RhoGDI2-Y24E, GST-RhoGDI2-Y130E, or GST-RhoGDI2 Y153F were induced by 1 mM IPTG, sonicated, and purified by using GST-BindTM resin beads according to the manufacturer’s instructions.
Next, 600 ng recombinant human active Src was co-incubated with 100 µM ATP, 1.2 µg of GST-RhoGDI2 (WT or mutated) fusion protein in 40 µl of kinase buffer (5 mM β-glycerophosphate, 25 mM Tris, pH 7.5, 2 mM DTT, 1 mM Na3VO4, 10 mM MgCl2) at 30°C for 30 min. The reactions were terminated by boiling with 10 µl of 5× Loading buffer.
together at 98°C for 5 min. Then samples were resolved by SDS-PAGE. CCRF-CEM cells were stimulated at 37°C with CXCL12 (25 ng/ml) for 30 min, and active ABL1 were immunoprecipitated using ABL1 antibody as previously described (17). Immunoprecipitates were washed with kinase buffer and added to the kinase buffer containing containing 2 µg of GST-RhoGDI2 mutated fusion protein.

**Western Blot Assay**

JURKAT or CCRF-CEM cells (3 × 10^6 per sample) were stimulated as described above and lysed in lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Non-ideit P-40, 2.5 mM sodium pyrophosphate, 1 mM glycerophosphate, 1 mM Na_3VO_4, 1 mM NaF, and 20 µg/ml aprotin/leupeptin/PMFS). Lysates were centrifuged at 4°C, 13,000 × g for 30 min, and the supernatants were collected. Then, 30 µg of each sample was resolved by SDS-PAGE, and proteins were transferred to nitrocellulose membranes. The membranes were washed with TBST and blocked with 5% non-fat dry milk or 3% BSA and then incubated overnight at 4°C with each indicated primary Ab and HRP-conjugated secondary Ab. Signal was detected using ECL Plus chemiluminescent detection system (Amersham).

**Statistical Analysis**

Results were tested for statistical significance using Student’s t-test and presented as means ± SD. Before Student’s t-test, normal distribution of the data were analyzed. For groups that were not normally distributed, Mann–Whitney tests were used. Significance was determined as *p < 0.05, **p < 0.01, ***p < 0.001.

**RESULTS**

**CXCR4 Is Required for ALL Cell Migration Toward CXCL12**

It has been demonstrated that CXCR4 is relative to infiltration of T-ALL cells (4–8, 18); meanwhile, CXCR4 cognate ligand CXCL12 is a chemokine that induces cell
migration (19). To identify the role of CXCR4 in T-ALL cell migration, JURKAT and CCRF-CEM ALL cell lines were pre-incubated with or without the antagonist of CXCR4, AMD3100 in each transwell assay. The results show that AMD3100 inhibits cell migration toward CXCL12 (Figures 1A,B). After CXCR4 in JURKAT and CCRF-CEM cells was reduced by shRNAs (Figures 1C,D), another transwell assay was conducted. The results show that CXCR4 shRNAs significantly reduce cell migration toward CXCL12 (Figures 1E,F). Therefore, CXCR4 is required for T-ALL cell migration toward CXCL12.

RhoGDI2 Inhibits CXCR4-Mediated T-ALL Cell Migration Toward CXCL12

RhoGDI2 is reported to negatively or positively regulate RhoGTPases (20). We previously demonstrated that RhoA and RhoC were required for JURKAT migration toward CXCL12 (Figures 3A,B). To investigate the effect of RhoGDI2 on CXCR4-mediated migration, we infected JURKAT and CCRF-CEM cells with lentivirus expressing GFP-RhoGDI2-WT, Y24E, Y130E, or Y153E. The expression levels of WT or mutated RhoGDI2 were detected 48 h after infection by Western blot, using GFP antibody. (C,D) Transfected cells were used in the transwell assay. Each experiment was repeated at least three times. Western blot bands were analyzed using Image Pro Plus 6.0, and fold changes of GFP, GFP-RhoGDI2-WT, or mutants were normalized according to ACTB. ACTB was used as the loading controls. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
CXCL12 (21). Therefore, we hypothesized that RhoGDI2 may play a critical role in CXCR4-mediated T-ALL cell migration. To identify the role of RhoGDI2 in the migration mediated by CXCR4, shRNAs to RhoGDI2 were generated and transfected into JURKAT or CCRF-CEM cells. Results show that RhoGDI2 sh2 significantly reduces the amount of RhoGDI2 in both cell lines (Figures 2A,B). Therefore, RhoGDI2 sh2 was used in the following transwell assay. Results show that RhoGDI2 sh2 significantly reduces the cell number migrated to CXCL12, indicating that RhoGDI2 inhibits CXCR4-mediated T-ALL migration toward CXCL12 (Figures 2C,D).

Phosphorylation of RhoGDI2 on Y24 and Y153 Negatively Regulates Its Inhibition to CXCR4-Mediated ALL Migration by Releasing RhoA and RhoC From RhoGDI2

Previous studies report tyrosine-phosphorylation of RhoGDI2 on Y24, Y130, and Y153 (16, 22). To evaluate the effects of RhoGDI2 phosphorylation on RhoA, RhoC, and CXCL12-induced ALL migration, Y24, Y130, or Y153 were mutated into Glu (E) to mimic the phosphorylation station following relevant reference (23). Results show that phosphorylation of RhoGDI2 on Y24, Y130, or Y153 recovered CXCL12-mediated ALL migration (Figures 3A–D).

Phosphorylation of RhoGDI2 has been reported to stabilize the RhoA-RhoGDI complex in neutrophil cytosol (24). GST pull-down results show that RhoGDI2 24E or RhoGDI2 153E bind less RhoA and RhoC than RhoGDI2 130E does; however, they all bound less RhoA and RhoC than wild-type RhoGDI2 does (Figures 4A,B), suggesting that phosphorylation of Y24 or Y153 dissociates RhoA or RhoC from RhoGDI2 and accelerates the activation of RhoA and RhoC although the phosphorylation of Y130 has less effects on RhoA or RhoC activation.

Src Is Activated by CXCL12 and Responsible for the Phosphorylation of RhoGDI2 on Y153

It has been previously reported that the Src family kinase was activated and plays a role in tyrosine-phosphorylation in migration cell migration (25). CXCL12 induces migration via Src-mediated CXCR4-EGFR cross-talk in gastric cancer cells (26). Therefore, we detected the activation of Src in CXCL12-treated JURKAT and CCRF-CEM cells. The results show that Src is activated in both cell lines (Figures 5A,B), providing a prerequisite for phosphorylation of RhoGDI2. To identify which tyrosine amino acid is phosphorylated by Src, active Src and specific mutants were used in the in vitro kinase assay. Results show that Src is critical for the phosphorylation of RhoGDI2 on Y153 (Figure 5C).

Furthermore, siRNA to Src was transfected into JURKAT and CCRF-CEM cells. Results show that migration is inhibited by
FIGURE 5 | CXCL12 can activate Src in T-ALL cells. (A, B) Starved JURKAT or CCRF-CEM cells were incubated with CXCL12, and then cell lysates were prepared. 60 µg of cell lysates were subject to SDS-PAGE and Western blot assay, using active Src antibody, Src(416Tyr-P). (C) Then, 1.2 µg of GST-RhoGDI2-WT, GST-RhoGDI2-Y24F, GST-RhoGDI2 Y130F, or GST-RhoGDI2 Y153F were incubated with 600 ng recombinant human active Src (His-tag) in the in vitro kinase assay. Samples were boiled in 1× Loading buffer at 98°C for 5 min and then resolved by SDS-PAGE. PY20, His antibody, or GST antibody was used in the Western blot assay to detect the phosphorylation of RhoGDI2, the amount of active Src, or RhoGDI2 (WT or mutated) that were used in each in vitro kinase assay, respectively. Western blot bands were analyzed using Image Pro Plus 6.0. Fold changes of active Src were normalized according to total Src. Bands of phosphorylated GST-RhoGDI2 (PY20) were normalized according to WT or mutants of GST-RhoGDI2 (GST) that were used in each kinase assay.
Luo et al. RhoGDI2 in T-ALL Cell Migration

FIGURE 6 | Knockdown expression of Src by siRNAs inhibited CXCR4-mediated T-ALL migration toward CXCL12. (A,B) siRNAs were transfected into JURKAT or CCRF-CEM cells using the methods described in the materials and methods section; 48 h after transfection, cell lysates were prepared for Western blot assay to detect the interference efficiency of siRNAs on Src. (C,D) Transfected cells were used in the transwell assay. Each experiment was repeated at least three times. Western blot bands were analyzed using Image Pro Plus 6.0, and fold changes of Src were normalized according to ACTB. ACTB was used as the loading controls.

siRNA (Figures 6A–D), demonstrating that Src is required for CXCR4-mediated leukemia cell migration toward CXCL12.

ABL1 Is Activated by CXCL12 and Responsible for the Phosphorylation of RhoGDI2 on Y24 and Y130

GPS 5.0 predicted that Y24 may be phospholated by ABL1 (27), and KinasePhos prediction results show that Y130 may be phosphorylated by ABL1 (28). Therefore, we tested the activation of ABL1 in the CXCR4 signaling pathway and found that ABL1 is activated in response to CXCL12 (Figures 7A,B). Active ABL1 can phosphorylate RhoGDI2 on Y24 and Y130 (Figure 7C).

Furthermore, Src family kinase Lck is absolutely required for the proliferation and survival of T-ALL cells that depend on NUP214-ABL1 activity (29). Therefore, activation of Lck was detected after cells were stimulated with CXCL12. Results show that Lck is activated by CXCL12 (Figures 8A,B). The migration of T-ALL cells mediated by CXCR4 is inhibited when siRNAs to
FIGURE 7 | CXCL12 can activate ABL1 in T-ALL cells. (A,B) Starved JURKAT or CCRF-CEM cells were incubated with CXCL12, and then cell lysates were prepared. 500 µg of cell lysates were incubated with GST-Crk-CTD in the GST pull-down assay, followed by Western blot assay, using the antibody to ABL1. Western blot bands were analyzed using Image Pro Plus 6.0, and fold changes of active ABL1 were normalized according to GST-CRK-CTD. Total ABL1 was used as another loading control. (C) Next, 2 µg of GST-RhoGDI2-Y24F, GST-RhoGDI2 Y130F, or GST-RhoGDI2 Y153F were introduced and incubated with active ABL1 immunoprecipitated from CCRF-CEM cells treated with CXCL12 at 37°C for 30 min in the in vitro kinase buffer for 30 min. Samples were boiled in 1× Loading buffer at 98°C for 5 min and then resolved by SDS-PAGE. PY20, ABL1, or GST antibody was used in the Western blot assay to detect the phosphorylation of RhoGDI2, the amount of active ABL1, or RhoGDI2 (WT or mutated) that we used in each in vitro kinase assay, respectively. Phosphorylated RhoGDI2 were normalized according to the mutants of GST-RhoGDI2. ABL1 was used as another loading control.

Lck, whose sequences are shown in Table 1, were transfected into JURKAT or CCRF-CEM cells (Figures 8C,D).

Finally, siRNA to ABL1 was transfected into JURKAT and CCRF-CEM cells. Results show that migration is inhibited by siRNA (Figures 9A–D), demonstrating that ABL1 is required for CXCR4-mediated leukemia cell migration toward CXCL12.

Taken together, RhoGDI2 is a critical signal molecule downstream of CXCR4. CXCL12/CXCR4 triggers the activation of downstream kinases, including Src and ABL1 responsible for the phosphorylation of RhoGDI2 on Y153, Y24, and Y130. Phosphorylation of RhoGDI2 on Y24 and Y153 releases RhoA and RhoC from RhoGDI2, which recovers CXCR4-mediated migration toward CXCL12 although the phosphorylation of Y130 has less effect on RhoA or RhoC binding. Therefore, RhoGDI2 may be a brake for CXCR4-positive T-ALL migration (Figure 10).

DISCUSSION

Xenotransplantation of NSG mice with Jurkat or CCRF-CEM cells demonstrates that both can infiltrate the CNS at similar proportions and that antagonizing CXCR4 prevents the clinical features of the disease and T-ALL cell CNS tropism (4). Pediatric acute lymphoid leukemia-phase II (TARGET, 2018) data from cBioPortal for cancer genomics (30, 31) reveals that
Lck was activated by CXCL12 and knocked down the expression of Lck by siRNA-inhibited CXCR4-mediated T-ALL migration toward CXCL12. (A,B) Starved JURKAT or CCRF-CEM cells were incubated with CXCL12, and then cell lysates were prepared. 60 µg of cell lysates were subjected to SDS-PAGE and Western blot assay, using active Lck antibody, Lck (394 Tyr-P). Western blot bands were analyzed using Image Pro Plus 6.0, and fold changes of active Lck were normalized according to total Lck. Total ABL1 was used as another loading control. (C,D) siRNAs were transfected into JURKAT or CCRF-CEM cells using the methods described in the materials and methods section; 48 h after transfection, cells were used in the transwell assay. Each experiment was repeated at least three times, and three repeats were included each time. **p < 0.01 comparing with the negative control (CXCL12−) group. ##p < 0.01 comparing with the positive control (CXCL12+) group.
Knockdown expression of ABL1 by siRNAs inhibited CXCR4-mediated T-ALL migration toward CXCL12. (A,B) siRNAs were transfected into JURKAT or CCRF-CEM cells using the methods described in the materials and methods section; 48 h after transfection, cell lysates were prepared for Western blot assay to detect the interference efficiency of siRNAs on ABL1. Western blot bands were analyzed using Image Pro Plus 6.0, and fold changes of ABL1 were normalized according the loading control ACTB. (C,D) Transfected cells were used in the transwell assay. Each experiment was repeated at least three times. *p < 0.05, ***p < 0.001, comparing with the negative control (CXCL12−) group. #p < 0.05, ###p < 0.001, comparing with the positive control (CXCL12+) group.

RhoGDI2 gene ARHGDIB deep depletion is closely relative to the bone marrow site of relapse in B-ALL. However, due to the restriction of the database source, the role of RhoGDI2 in T-ALL progression remains to be investigated. Here, we find that RhoGDI2 is phosphorylated by Src and ABL1 in response to CXCR4 stimulation by CXCL12 in T-ALL cell lines and that RhoGDI2 decreases the CXCR4-mediated T-ALL cell line migration toward CXCL12 (Figures 1, 2). Because migration is necessary for infiltration and consequent relapse of leukemia, it would be interesting to explore whether RhoGDI2 brakes CXCR4-mediated T-ALL infiltration in vivo.

Recent reports show that RhoGDI2 participates in β1 inside-out signaling (16) and β2 outside-in signaling (20) in T lymphocytes. Phosphorylations of p85-bound RhoGDI2 on Y130 and Y153 by c-Abl and Src are required for the complex to be recruited to PSGL1 and thereby regulates β1 integrin-mediated T cell adhesion to VCAM-1 (16). Upon P-selectin glycoprotein ligand-1 engagement, RhoGDI2 is phosphorylated at Y24 and Y153 by Src, ABL1, and Syk (20). In bladder...
cancer, it was demonstrated that, except Y153, Y24 was also the primary Src phosphorylation site (22). The Y24 mutant also showed a partial reduction in phosphorylation by Src, which was significant in HEK293T but noticeably less in UMUC3 human bladder cancer cells. Src phosphorylation in RhoGDI2 has been involved in migration of neutrophils toward fMLP (24). In our in vitro kinase assay, results show that active Src primarily activates Y153 rather than Y24 of RhoGDI2 (Figure 5C).

Proteomic analyses have identified phosphorylation in Y24 of RhoGDI2 in pervanadate-treated JURAT cells, an established leukemic T-cell line (32, 33). Using JURKAT and CCRF-CEM T-ALL cell lines, we find that RhoGDI2 Y24 and Y130 are phosphorylated by ABL1 (Figure 7C). Although ABL1 is reported to phosphorylate Y130 of p85-bound RhoGDI2 upon PSGL-1 ligation (16), we haven’t found any scholarly report that ABL1 phosphorylation in Y24 and Cdc42 (20), we find the phosphorylation on 24 and 153 tyrosine complex less RhoA or RhoC in human T-ALL cell lines (Figure 3), raising a possibility to release the negative regulatory role of RhoGDI2 in T-ALL cell migration toward CXCL12 (Figure 4).

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

JL and JW designed the study, collated the data, and carried out data analyses. JW and HZ conducted the experiments. JL produced the initial draft of the manuscript. JW and LW contributed to drafting the manuscript. All authors have read and approved the final submitted manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (grant no. 31401216), Research Project Supported by the Shanxi Scholarship Council of China (grant no. 2017-012), and the Natural Science Foundation of Shanxi Province of China (grant no. 201901D111010).

ACKNOWLEDGMENTS

GFP-tagged WT human RhoGDI2 in lentiviral pWPXLd vector and shRNAs targeting RhoGDI2 or random control in lentiviral pDSL_hpUGIP vector were kindly provided by Professor Xianlu Zeng from Northeast Normal University, Changchun, China. We wish to thank Prof. M. James C. Crabbe in Wolfson College, University of Oxford, for suggestions and revision of the manuscript.
REFERENCES

1. Wu C, Li W. Genomics and pharmacogenomics of pediatric acute lymphoblastic leukemia. Crit Rev Oncol Hematol. (2018) 126:100–11. doi: 10.1016/j.critrevonc.2018.04.002

2. Inaba H, Geraves M, Mullighan CG. Acute lymphoblastic leukemia. Lancet. (2013) 381:1943–55. doi: 10.1016/s0140-6736(12)62187-4

3. Ko RH, Li L, Barnette P, Bostrom B, Hutchinson R, Raetz E, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia consortium study. J Clin Oncol. (2010) 28:648–54. doi: 10.1200/jco.2009.22.2950

4. Jost TR, Borgia C, Radaelli E, Romagnani A, Perruzza L, Omodho L, et al. Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia. J Leukoc Biol. (2016) 99:1077–87. doi: 10.1189/jlb.sma0915-394R

5. Matsutomo T, Jimi S, Hara S, Takamatsu Y, Suzumiya J, Tamura K. Am80 inhibits stomal cell-derived factor-1-induced chemotaxis in T-cell acute lymphoblastic leukemia cells. Leuk Lymphoma. (2010) 51:507–14. doi: 10.3109/1042190090360180

6. Crazzolara R, Kreczy A, Mann G, Heitger A, Eibl G, Fink FM, et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukemia. Br J Haematol. (2001) 115:545–53. doi: 10.1046/j.1365-2457.2001.02946.x

7. Alsadeq A, Fedders H, Vokuhl C, Belau NM, Zimmermann M, Wirbelauer T, et al. The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system. Haematologica. (2017) 102:346–55. doi: 10.3324/haematologica.2016.174774

8. Annels NE, Willemsz AJ, van der Velden VH, Faaij CM, van Wering E, Sie-Go DM, et al. Possible link between unique chemokine and homing receptor expression at diagnosis and relapse location in a patient with childhood T-ALL. Blood. (2004) 103:2086–8. doi: 10.1182/blood-2003-06-1812

9. Vadillo E, Dorantes-Acosta E, Pelayo R, Schnoor M. T cell acute lymphoblastic leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. Blood Rev. (2018) 32:36–51. doi: 10.1016/j.blre.2017.08.006

10. Scherle P, Behrens T, Staudt LM. Ly-GDI, a GDP–dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes. Proc Natl Acad Sci USA. (1993) 90:7568–72. doi: 10.1073/pnas.90.16.7568

11. Boulter F, Garcia-Mata R, Guilloy C, Dubash A, Rossi G, Breenwald PJ, et al. Regulation of Rho GT-Pase crosstalk, degradation and activity by RhoGDI1. Nat Cell Biol. (2010) 12:477–83. doi: 10.1038/nclb2049

12. Adra CN, Ko J, Leonard D, Wirth LJ, Cerione RA, Lim B. Identification of a novel protein with G DP dissociation inhibitor activity for the ras-like proteins CDC42Hs and rac 1. Genes Chromosomes Cancer. (1993) 6:253–61. doi: 10.1002/1091-230X(199305)6:3<253::AID CCC421>3.0.CO;2-H

13. Scheffzek K, Stephan I, Jensen ON, Illenberger D, Gierschik P. The Rac-RhoA GTP-binding protein, is expressed preferentially in lymphocytes. Proc Natl Acad Sci USA. (1993) 90:7568–72. doi: 10.1073/pnas.90.16.7568

14. Luo J, Xu T, Li C, Ba X, Wang X, Jiang Y, et al. p85-RhoGDI2, a novel complex, whose overexpression leads to disruption of the actin cytoskeleton. Mol Biol Cell. (2009) 114:2961–8. doi: 10.1182/blood-2008-11-189308